U.S. Markets closed
  • S&P 500

    3,629.65
    -5.76 (-0.16%)
     
  • Dow 30

    29,872.47
    -173.77 (-0.58%)
     
  • Nasdaq

    12,094.40
    +57.62 (+0.48%)
     
  • Russell 2000

    1,845.02
    -8.51 (-0.46%)
     
  • Crude Oil

    45.09
    -0.62 (-1.36%)
     
  • Gold

    1,817.80
    +6.60 (+0.36%)
     
  • Silver

    23.40
    +0.04 (+0.16%)
     
  • EUR/USD

    1.1913
    -0.0006 (-0.0477%)
     
  • 10-Yr Bond

    0.8780
    -0.0040 (-0.45%)
     
  • Vix

    21.25
    -0.39 (-1.80%)
     
  • GBP/USD

    1.3340
    -0.0043 (-0.3188%)
     
  • USD/JPY

    104.2830
    -0.1570 (-0.1503%)
     
  • BTC-USD

    17,268.43
    -710.74 (-3.95%)
     
  • CMC Crypto 200

    337.05
    -33.47 (-9.03%)
     
  • FTSE 100

    6,351.25
    -39.84 (-0.62%)
     
  • Nikkei 225

    26,537.31
    +240.45 (+0.91%)
     

Zai Lab Announces Upcoming Presentations in November Investor Conferences

Zai Lab Limited
·2 min read

SHANGHAI and SAN FRANCISCO, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial stage biopharmaceutical company, today announced that management from Zai Lab will present at the following upcoming virtual investor conferences in November. Details are as follows:

Citi China Investor Conference 2020
Presentation: Thursday, November 5, 2020 at 1:00 p.m. HKT

BioCentury 7th China Healthcare Summit
Panel Discussion: Thursday, November 12, 2020 at 2:00 p.m. HKT

23rd Nomura Investment Forum 2020
Presentation: Thursday, November 12, 2020 at 2:30 p.m. HKT

Goldman Sachs Asia Pacific Healthcare Forum 2020
Panel Discussion: Tuesday, November 17, 2020 at 10:00 a.m. HKT

Jefferies Virtual London Healthcare Conference
Presentation: Wednesday, November 18, 2020 at 10:00 a.m. GMT

A live webcast of the Jefferies Virtual London Healthcare Conference presentation will be available under “Events & Presentations” in the “Investor Relations” section of Zai Lab’s website. An archived replay will be available for 90 days following the event.

About Zai Lab

Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, infectious and autoimmune diseases to patients in China and around the world. To quickly target the large, fast-growing segments of China’s pharmaceutical market and address unmet medical needs, Zai Lab’s experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates. Zai Lab has also built an in-house team with strong drug discovery and translational research capabilities, aiming to establish a global pipeline of proprietary drug candidates against targets in our focus areas. Zai Lab’s vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its portfolio in order to impact human health worldwide.

For additional information about the company, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global.

For more information, please contact:

ZAI LAB CONTACTS:

Zai Lab
Billy Cho, CFO
+86 137 6151 2501
billy.cho@zailaboratory.com

Media: Ryo Imai / Robert Flamm, Ph.D.
Burns McClellan, on behalf of Zai Lab
212-213-0006 ext. 315 / 364
rimai@burnsmc.com / rflamm@burnsmc.com

Investors: Pete Rahmer / Mike Zanoni
Endurance Advisors, on behalf of Zai Lab
415-515-9763 / 610-442-8570
prahmer@enduranceadvisors.com / mzanoni@enduranceadvisors.com

Zai Lab Limited

Source: Zai Lab Limited